Latest Health News

Alara Resources (ASX:AUQ) is seeking to raise $3.84 million through a pro-rata non-renounceable entitlement offer, partially underwritten by major shareholder ATI. The funds will primarily support exploration and working capital amid ongoing operational progress at its Oman copper projects.

Future Generation Australia (ASX: FGX) reported a robust 20.1% total shareholder return for the year to June 2026 alongside an increased fully franked interim dividend of 3.8 cents per share, maintaining its commitment to steady income and social impact.

ResMed is offloading its MatrixCare business in a $490 million cash deal, reinforcing its strategic pivot towards high-growth sleep and connected care markets. The sale proceeds will fuel shareholder returns and innovation investments.

A significant shareholder bloc opposing Floorscape's acquisition has forced Bremworth to abandon its Scheme of Arrangement, leaving the flooring manufacturer to pursue standalone growth amid tough market conditions.

Promisia Healthcare’s aged care occupancy climbed to a record 96% in June 2026, underpinning its FY27 earnings growth guidance. Aldwins House led the turnaround, while solar initiatives and wellness programs roll out across sites.

Summerset Group maintained stable new sales in Q2 2026 with a notable 26% jump in resales, while prudently reducing its New Zealand build rate in response to economic uncertainty.

PainChek announces the immediate departure of CEO Philip Daffas, with COO Andy Hoggan stepping in as interim leader amid a strategic pivot to boost US market growth following FDA clearance.

ReNerve Limited has secured regulatory approval to market its flagship NervAlign Nerve Cuff in Indonesia, marking a major step in its Asia-Pacific expansion and unlocking access to one of the region’s largest nerve repair markets.

Winton Land’s CEO and Chair Chris Meehan has resigned immediately during a board-led employment process, with independent director Steven Joyce appointed as Chair and an interim leadership reshuffle underway.

Enlitic has locked in binding commitments for a conditional A$15 million capital raise alongside a convertible note conversion, setting the stage for a clearer path to cashflow break-even and accelerated rollout of its SaaS platform.

Germany’s Hesse State Office has issued new GMP guidance that questions the viability of fragmented medicinal cannabis supply chains, reinforcing ECS Botanics’ integrated manufacturing approach and potentially tightening market supply.

Racura Oncology has secured Bellberry HREC approval for its HARNESS-1 lung cancer trial, enabling expansion to additional Australian sites including Chris O’Brien Lifehouse and Austin Health, setting the stage for accelerated patient enrolment.